Navigation Links
Medgenics Announces Encouraging Preliminary Data For Phase I/II Clinical Trial of EPODURE In Renal Anemia
Date:11/3/2008

Data will be presented during Renal Week 2008,November 4th through 9th in Philadelphia, Pennsylvania

MISGAV, Israel and LONDON, Nov. 3 /PRNewswire-FirstCall/ -- Medgenics (AIM: MEDG), is pleased to announce encouraging preliminary data for its Phase I/II clinical trial.

The landmark Phase I/II clinical trial of Medgenics' EPODURE Biopump, for providing sustained treatment of anemia in subjects with chronic kidney disease, is underway. The current trial is designed to assess the safety and efficacy of the EPODURE Biopump in providing sustained elevation of hemoglobin by delivering sufficient supplemental amounts of the protein erythropoietin (EPO) for 3-6 months. Each subject will be monitored for 6 months after the EPODURE implantation. Further applications of the Biopump platform technology will be developed and tested from 2009 onwards.

The first month's data from the on-going Phase I/II trial has now been collected from the initial two anemic, chronic kidney disease subjects receiving the lowest dose in this dose escalating study. One subject received 2 and the other 3 Biopumps, reflecting the respective number needed to provide the intended low daily EPO dose of 18-25 IU/kg/day in each subject. The hemoglobin levels of each of these subjects have risen and remain within the target range of between 10 and 12 grams per deciliter for a month, with no adverse effects reported or observed, other than minor localized bruising typically associated with skin biopsy and implant. The 10-12 grams per decilitre range is what is recommended for such patients to treat their anemia. As the trial progresses these subjects will continue to be monitored, additional subjects will be enrolled and further data will be reported as key milestones are achieved. The Directors expect to commence testing on further subjects before the end of 2008.

The Directors are encouraged by the fact that, although the trials are at an early stage, the elevated hemog
'/>"/>

SOURCE Medgenics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... Ames, IA (PRWEB) April 16, 2015 ... (CAST) announces that the prestigious 2015 Borlaug CAST ... honored faculty member at Tuskegee University in Alabama. ... by written material; public presentations; and/or the use ... excels in all three areas. As a specialist ...
(Date:4/16/2015)... MOSCOW , April 16, 2015 /PRNewswire/ ... (ChemRar), the Russian pharmaceutical investment and R&D ... announced collaboration for research, development and commercialization ... with the intention to stimulate ... industry.      (Logo: http://photos.prnewswire.com/prnh/20150416/739742-a) ,     ...
(Date:4/16/2015)...  EMD Serono today announced the US biopharmaceutical ... , appointed Alise Reicin , MD, ... Development.  Dr. Reicin brings extensive research and early/late ... Immunology. She is an accomplished pharmaceutical executive with ... President in various capacities across R&D at MSD ...
(Date:4/16/2015)... (PRWEB) April 16, 2015 Dana-Farber ... Cancer Science and Resolution Bioscience, Inc. today announced ... co-develop a novel, blood-based, clinic ready, Next Generation ... (NSCLC). The collaboration is the first to demonstrate ... and ROS1 fusions in blinded plasma samples and ...
Breaking Biology Technology:The 2015 Borlaug CAST Communication Award Goes to Channapatna Prakash 2Lancet and ChemRar High Tech Center Have Announced a Partnership in the Development and Production of Novel Drugs in Russia 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 3Resolution Bioscience announces successful collaboration on a novel, non-invasive, targeted NGS test for lung cancer 2Resolution Bioscience announces successful collaboration on a novel, non-invasive, targeted NGS test for lung cancer 3
... - TOPIC: The state of the microRNA market and the ... current and potential impact on drug discovery, molecular, ... Tuesday, March 31, 2009, - TIME: ... - HOST: Christi Bird, Senior Research Analyst, Healthcare, ...
... March 30 BioVex Inc, a company developing new ... and infectious disease, announced today it has raised $40 ... private financing.The placement was led by Forbion Capital Partners, ... Agricole Private Equity, Harris & Harris Group, Innoven Partners, ...
... software for clinical research trials has named Jovianna DiCarlo President ... years experience driving new pharmaceutical therapeutics and devices through the ... to commercialization. , ... Frederick, MD ...
Cached Biology Technology:Frost & Sullivan Hosts Presentation on MicroRNAs: From Stem Cells and Cancer to Diagnostics and Therapeutics 2BioVex Raises $40 Million in First Close of Series F Financing 2BioVex Raises $40 Million in First Close of Series F Financing 3Jovianna DiCarlo Named ConsentSolutions, Inc. President & Chief Executive Officer 2
(Date:4/14/2015)... NEW YORK , April 14, 2015 /PRNewswire/ ... Fast IDentity Online (FIDO ® ) Alliance tm ... standards-based specifications. FIDO members commit to share technology ... authentication methods that are interoperable, more secure and ... specifications enable biometric identity verification that protects sensitive ...
(Date:4/13/2015)... YORK , April 13, 2015 ... by TechSci Research, "Global Biometrics Market Forecast & Opportunities, ... register a CAGR of around 14% till 2020. ... governments for large scale implementation and review of ... and launch of new products with greater efficiency, ...
(Date:4/10/2015)... , April 10, 2015 Research ... of the "Security Competitive Profiles - NEC" ... , NEC will continue to supply a ... the market, with a company focus on the development ... Winning opportunities in the Asia-Pacific ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NEC Security Competitive Profile 2015 2
... inside each cell, a little engine called RNA polymerase II ... the nucleus that get carried to production units in the ... researchers at the University of Michigan Medical School have shown ... for damage. When certain types of damage in DNA halt ...
... LAFAYETTE, Ind. - A biomedical engineer at Purdue University ... that promises to be more effective than standard CPR ... by 25 percent over the current method. A ... a success rate of 5 percent to 10 percent, ...
... (09/05/07)--It is well established that a child,s brain has ... the extent to which such plasticity exists in the ... and Johns Hopkins University have used converging evidence from ... adult visual cortex does indeed reorganize-and that the change ...
Cached Biology News:Enzyme alerts cell's powerful army to repair DNA damage 2Enzyme alerts cell's powerful army to repair DNA damage 3New CPR promises better results by compressing abdomen, not Chest 2New CPR promises better results by compressing abdomen, not Chest 3New CPR promises better results by compressing abdomen, not Chest 4Adult brain can change, study confirms 2
...
... This monoclonal antibody recognizes 30% ... unrelated individuals. It does not ... proteins lacking rheumatoid factor nor with ... be used in ELISA to detect ...
...
Human VEGF R2 (KDR) MAb (Clone 89106)...
Biology Products: